QuartzBio, a life science technology company delivering portfolio‑scale sample and biomarker intelligence for clinical‑stage biopharma, announces a strategic growth investment and controlling interest from Eir Partners, a private equity firm focused on health tech and tech-enabled services. The move marks a significant milestone as QuartzBio expands its role as trusted infrastructure for biopharma organizations seeking greater operational control, data integrity, and efficiency across complex clinical trial portfolios. QuartzBio is trusted by a growing customer base that includes multiple Top 10 pharmaceutical companies, delivering operational clarity across complex clinical programs.
Read the full article: QuartzBio Secures Growth Investment from Eir Partners to Accelerate Clinical Trial Intelligence //
Source: https://www.prnewswire.com/news-releases/quartzbio-secures-growth-investment-from-eir-partners-to-accelerate-clinical-trial-intelligence-302770017.html